Cantor Fitzgerald Analysts Lift Earnings Estimates for HRMY

Key Points

• Cantor Fitzgerald analysts raised their FY2025 earnings estimate for Harmony Biosciences to $2.29 per share from a previous forecast of $2.19, maintaining a "Strong-Buy" rating on the stock.
• The company posted a quarterly EPS of $0.68, missing expectations of $0.78, while revenue increased by 16% year-over-year to $200.49 million.
• Analysts are divided on the stock, with a consensus rating of "Moderate Buy" and an average price target of $51.00, reflecting varied opinions from multiple research firms.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Harmony Biosciences in a report issued on Thursday, August 7th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of $2.29 for the year, up from their prior forecast of $2.19. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. Cantor Fitzgerald also issued estimates for Harmony Biosciences' FY2026 earnings at $2.17 EPS.

HRMY has been the subject of several other research reports. Mizuho lifted their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Thursday, May 15th. The Goldman Sachs Group began coverage on shares of Harmony Biosciences in a report on Thursday, July 10th. They issued a "neutral" rating and a $33.00 target price for the company. Wall Street Zen downgraded shares of Harmony Biosciences from a "buy" rating to a "hold" rating in a report on Saturday. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $55.00 price target (up previously from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. Finally, Oppenheimer assumed coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price target for the company. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Harmony Biosciences has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Harmony Biosciences Price Performance

Harmony Biosciences stock opened at $34.19 on Monday. Harmony Biosciences has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. The firm has a 50 day moving average price of $34.16 and a 200 day moving average price of $33.78. The company has a market capitalization of $1.97 billion, a PE ratio of 11.03, a price-to-earnings-growth ratio of 0.40 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing the consensus estimate of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The company had revenue of $200.49 million during the quarter, compared to analyst estimates of $204.37 million. During the same quarter last year, the business posted $1.05 EPS. The firm's revenue for the quarter was up 16.0% on a year-over-year basis.

Institutional Investors Weigh In On Harmony Biosciences

Several institutional investors have recently modified their holdings of the company. Deep Track Capital LP acquired a new position in shares of Harmony Biosciences during the fourth quarter worth $49,894,000. Boston Partners acquired a new position in shares of Harmony Biosciences during the second quarter worth $19,398,000. Marshall Wace LLP raised its position in shares of Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock worth $31,992,000 after acquiring an additional 579,103 shares in the last quarter. New Vernon Capital Holdings II LLC lifted its stake in Harmony Biosciences by 3,219.0% during the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company's stock worth $16,211,000 after purchasing an additional 473,708 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in Harmony Biosciences by 173.9% during the fourth quarter. Invesco Ltd. now owns 449,180 shares of the company's stock worth $15,456,000 after purchasing an additional 285,156 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.